Litigation Details for Par Pharmaceutical Inc. v. Breckenridge Pharmaceutical Inc. (D. Del. 2015)
✉ Email this page to a colleague
Par Pharmaceutical Inc. v. Breckenridge Pharmaceutical Inc. (D. Del. 2015)
| Docket | ⤷ Sign Up | Date Filed | 2015-11-10 |
| Court | District Court, D. Delaware | Date Terminated | 2016-01-24 |
| Cause | 35:271 Patent Infringement | Assigned To | Sue Lewis Robinson |
| Jury Demand | None | Referred To | |
| Patents | 6,592,903; 7,101,576; 9,040,088; 9,101,540; 9,101,549; 9,107,827 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Par Pharmaceutical Inc. v. Breckenridge Pharmaceutical Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Par Pharmaceutical Inc. v. Breckenridge Pharmaceutical Inc. (D. Del. 2015)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2015-11-10 | 1 | infringes U.S. Patent Nos. 6,592,903 (the “’903 Patent”) and 7,101,576 …infringement of U.S. Patent Nos. 9,101,540 (the “’540 Patent”), 9,101,549 (the “’549 Patent”), and 9,107,827…9,107,827 (the “’827 Patent”) (collectively, the “Patents-in-Suit”) pursuant to the Patent Laws of the United…IV Certification”). The ’903 and ’576 Patents, like the Patent-in-Suit, cover Par’s Megace® ES drug product…owner of the ’540, ’549, and ’827 Patents. 16. The ’540 Patent, entitled “Nanoparticulate Megestrol | External link to document | |
| 2016-01-24 | 13 | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,101,540 B2; 9,101,549 B2; 9,107,827…2015 25 January 2016 1:15-cv-01039 830 Patent None District Court, D. Delaware | External link to document | |
| 2015-11-10 | 4 | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 9,101,540 B2; US 9,101,549 …2015 25 January 2016 1:15-cv-01039 830 Patent None District Court, D. Delaware | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
